Rhygaze Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $86.7M

  • Investors
  • 5

Rhygaze General Information

Description

Developer of novel gene therapy designed to restore vision in patients. The company's therapy technology delivers a light-sensor gene specifically to cone cells that have lost light sensitivity, and repair their ability to detect light, enabling the healthcare industry to provide vision restoration for patients suffering from blindness.

Contact Information

Website
www.rhygaze.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Mittlere Strasse 91
  • 4031 Basel
  • Switzerland
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Other Pharmaceuticals and Biotechnology
Vertical(s)
HealthTech
Corporate Office
  • Mittlere Strasse 91
  • 4031 Basel
  • Switzerland

Rhygaze Timeline

20252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rhygaze Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 05-Dec-2024 $86.7M Completed Pre-Clinical Trials
1. Seed Round 17-Jul-2024 Completed Pre-Clinical Trials
To view Rhygaze’s complete valuation and funding history, request access »

Rhygaze Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed
To view Rhygaze’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Rhygaze Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rhygaze Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
F-Prime Venture Capital Minority
GV Corporate Venture Capital Minority
BioGeneration Ventures Venture Capital Minority
Novartis Venture Fund Corporate Venture Capital Minority
To view Rhygaze’s complete investors history, request access »

Ready to get started?

Request a free trial

Rhygaze FAQs

  • When was Rhygaze founded?

    Rhygaze was founded in 2024.

  • Where is Rhygaze headquartered?

    Rhygaze is headquartered in Basel, Switzerland.

  • What is the size of Rhygaze?

    Rhygaze has 5 total employees.

  • What industry is Rhygaze in?

    Rhygaze’s primary industry is Therapeutic Devices.

  • Is Rhygaze a private or public company?

    Rhygaze is a Private company.

  • What is Rhygaze’s current revenue?

    The current revenue for Rhygaze is .

  • How much funding has Rhygaze raised over time?

    Rhygaze has raised $97.9M.

  • Who are Rhygaze’s investors?

    ARCH Venture Partners, F-Prime, GV, BioGeneration Ventures, and Novartis Venture Fund have invested in Rhygaze.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process